Trial Profile

Prospective, Randomized, Double-blind Study, Placebo-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in Treatment of Excessive Daytime Sleepiness in Narcolepsy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pitolisant (Primary) ; Modafinil
Indications Cataplexy; Narcolepsy
Focus Registrational; Therapeutic Use
Acronyms Harmony-I
Sponsors Bioprojet

Most Recent Events

06 Jun 2022 According to a Harmony Biopharm media release, results of post hoc, pooled analyses from the HARMONY-1 and HARMONY-CTP trials, was presented at the 36th Annual Meeting of the Associated Professional Sleep Societies (APSS).
06 Jun 2022 Results published in the Media Release
12 Dec 2021 Results published in the CNS Drugs

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com